Chlorpromazine, Hydrochloride (CAS 69-09-0)

Chlorpromazine, Hydrochloride (CPZ-HCl) is a phenothiazine-based compound that has been widely used to research various mental health disorders, including schizophrenia, bipolar disorder, and depression. It possesses potent antipsychotic, anxiolytic, and sedative properties and is also investigated for alleviating symptoms such as nausea, vomiting, and hiccups. Chlorpromazine, Hydrochloride acts as an inhibitor of calmodulin-dependent stimulation of cyclic nucleotide phosphodiesterase (PDE) and displays D2DR inhibition. Moreover, it exhibits α-adrenergic blocking action. Chlorpromazine, Hydrochloride is known to inhibit Eg5, Histamine H1 Receptor, NOS1, and PLA2. The biochemical and physiological effects of Chlorpromazine, Hydrochloride are diverse. It has been observed to inhibit the reuptake of dopamine and serotonin, monoamine oxidase, calcium channels, adenylate cyclase, and phosphodiesterases. Furthermore, it can influence the production of hormones such as prolactin, corticosterone, and thyroid hormones. The primary mode of action of Chlorpromazine, Hydrochloride involves the blockade of dopamine receptors in the brain, resulting in reduced dopamine transmission and diminished stimulation of postsynaptic neurons. Additionally, it affects serotonin receptors, leading to decreased serotonin transmission and lowered stimulation of postsynaptic neurons. Chlorpromazine, Hydrochloride also interacts with other neurotransmitter systems, including norepinephrine and acetylcholine, resulting in attenuated stimulation of postsynaptic neurons. With its extensive usage in scientific research, Chlorpromazine, Hydrochloride serves as useful for investigating cellular signaling pathways and neuroscience phenomena.